De-escalated administration of bone-targeted agents in patients with breast and prostate cancer—A survey of Canadian oncologists
Open Access
- 1 June 2013
- journal article
- Published by Elsevier in Journal of Bone Oncology
- Vol. 2 (2) , 77-83
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- A national portfolio of bone oncology trials—The Canadian experience in 2012Journal of Bone Oncology, 2012
- Bone-Targeted Agents and Skeletal-Related Events in Breast Cancer Patients with Bone Metastases: The State of the ArtCurrent Oncology, 2012
- Time to Put an End to the “One Size Fits All” Approach to Bisphosphonate Use in Patients with Metastatic Breast Cancer?Current Oncology, 2012
- Prevention and treatment of bone metastasesNature Reviews Clinical Oncology, 2011
- Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologistsSupportive Care in Cancer, 2011
- Treatment Persistence With Monthly Zoledronic Acid is Associated With Lower Risk and Frequency of Skeletal Complications in Patients With Breast Cancer and Bone MetastasisClinical Breast Cancer, 2011
- American Society of Clinical Oncology Clinical Practice Guideline Update: Recommendations on the Role of Bone-Modifying Agents in Metastatic Breast CancerJournal of Oncology Practice, 2011
- Bisphosphonate use for the management of breast cancer patients with bone metastases: A survey of Canadian Medical OncologistsSupportive Care in Cancer, 2004
- Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone MetastasesNew England Journal of Medicine, 1996
- Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosagesThe American Journal of Medicine, 1993